glutathione

Overview

Glutathione (GSH) is a small thiol-containing tripeptide composed of glutamate, cysteine, and glycine. It is one of the most abundant intracellular antioxidants in mammalian cells and is central to redox homeostasis, detoxification, and protection against oxidative damage. By directly scavenging reactive species and serving as a substrate for glutathione peroxidases and glutathione S-transferases (GSTs), it helps regulate lipid peroxidation, protein oxidation, and cellular responses to electrophilic stress.

In biomedical research, glutathione is frequently treated as both a biomarker and a functional target. Elevated or depleted GSH levels are used to characterize oxidative stress, ferroptosis susceptibility, inflammatory injury, and drug resistance. Because many tumors maintain high intracellular GSH to buffer oxidative stress, glutathione has become a major focus in cancer nanomedicine and redox-responsive drug delivery, where GSH-cleavable disulfide bonds, GSH-triggered release systems, and GSH depletion strategies are used to amplify photodynamic therapy, chemodynamic therapy, cuproptosis, and ferroptosis.

Focus of Latest Publications

Recent publications portray glutathione as a major determinant of cellular redox balance and a practical target for therapy design. In multiple cancer studies, high glutathione levels in the tumor microenvironment were exploited as a trigger for drug release or as a metabolic weakness to induce ferroptosis. For example, GSH-responsive disulfide linkers were used in peptide-drug conjugates and self-assembling prodrugs to enable selective intracellular release in rheumatoid arthritis and ovarian cancer-related delivery systems. Similarly, several nanoplatforms were engineered to respond to elevated tumor glutathione, including glutathione-cleavable phototheranostic systems, redox-triggered polyprodrugs, and bioorthogonal nanocatalysts that used GSH to drive Cu(II)/Cu(I) cycling, deplete intracellular GSH, amplify lipid peroxidation, and induce ferroptotic cell death.

A major theme across the cancer literature was glutathione depletion as a mechanism to overcome antioxidant defenses. Studies in colorectal cancer, triple-negative breast cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, melanoma, and bladder cancer reported that lowering GSH enhanced reactive oxygen species accumulation, lipid peroxidation, mitochondrial dysfunction, and immunogenic stress signaling. Several reports linked GSH depletion to downregulation of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), reinforcing the role of glutathione metabolism in ferroptosis. Other studies combined glutathione depletion with photodynamic therapy, chemodynamic therapy, sonodynamic therapy, or checkpoint inhibitor, including atezolizumab-based and PD-L1-related strategies, to intensify antitumor effects.

Outside oncology, glutathione was repeatedly used as a biomarker of oxidative status and neuroprotection. In rat models of Alzheimer’s disease, Huntington’s disease, traumatic brain injury, MDMA exposure, cadmium-induced neurotoxicity, and ischemic stroke, reduced glutathione levels were associated with oxidative injury, inflammation, and apoptosis, while interventions such as resveratrol, genistein, pinostrobin, clemizole, silibinin meglumine, and diosgenin were reported to restore GSH alongside superoxide dismutase, catalase, and other antioxidant defenses. In these studies, glutathione was measured together with malondialdehyde, nitric oxide, acetylcholinesterase activity, Beta amyloid, brain-derived neurotrophic factor, and inflammatory mediators such as tumour necrosis factor-α and proinflammatory cytokines.

Glutathione also appeared in studies of antibacterial materials, pesticide delivery, wound dressings, and food-related nanocapsules, where it served as a redox-responsive trigger or a readout of oxidative protection. In one oral antibacterial platform, glutathione depletion contributed to bacterial death by enhancing reactive oxygen species generation. In another study, foliar-adhering microcapsules released pesticide more rapidly under higher glutathione concentrations, demonstrating GSH-sensitive environmental responsiveness. Across these diverse contexts, glutathione remained a central indicator of cellular stress, a mechanistic switch for controlled release, and a therapeutic target in redox-based intervention.

Key Publications

• NEWJun Antidepressant effects of transcranial static magnetic field stimulation and β-carotene nanoparticles in a rat model of depression. (Progress in neuro-psychopharmacology & biological psychiatry, 2026, PMID 42190987): "the levels of lipid peroxidation (MDA), nitric oxide (NO), reduced glutathione (GSH) and brain derived neurotrophic factor (BDNF) in both the cortex and hippocampus."
• Jun A GSH-scavenging and synthesis-blocking microneedle patch for augmenting photodynamic eradication of diabetic wound biofilms. (Journal of materials chemistry. B, 2026, PMID 42300219): "Nevertheless, the efficacy of PDT is substantially undermined by restricted ROS diffusion through compact biofilm structures and rapid ROS neutralization by overexpressed reduced glutathione (GSH) within the biofilm microenvironment."
• Jun A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors. (Cancer research, 2026, PMID 41833522): "GCLC inhibition led to the depletion of intracellular glutathione (GSH), an increase in reactive oxygen species, and elevated lipid peroxidation, ultimately inducing ferroptotic cell death."
• Jun Therapeutic Potential of Stearylamine-Conjugated Phenylboronic Acid-Modified Nanocarriers of 4-Allyl Pyrocatechol in Modulating Sialylation and Neuroinflammation in Scopolamine-Induced Cognitive Impairment in the Rat Model. (Molecular pharmaceutics, 2026, PMID 42267754): "The biochemical estimations like acetylcholinesterase activity were used; oxidative and antioxidant parameters like nitric oxide, malondialdehyde, and reduced glutathione were determined; enzyme-linked immunosorbent assays for amyloid beta, inflammatory cytokines, brain-derived neurotrophic factor, and CD33 were performed."
• Jun Nose-to-Brain delivery of genistein-loaded peppermint lipid nanocapsules for neuroprotection against Alzheimer's Disease: Formulation, Characterization, pharmacokinetic and Pharmacodynamic studies. (European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2026, PMID 41881284): "Biochemical analyses confirmed the enhanced oxidative defense (increased superoxide dismutase, reduced glutathione, and decreased malondialdehyde) and the inhibition of acetylcholinesterase enzyme."
• May Neuroprotective Potential of Pinostrobin in a Rat Model of Huntington's Disease: Behavioural, Biochemical, and Molecular Docking Evidence. (Molecular neurobiology, 2026, PMID 42213222): "The effect of PSB on 3-NPA induced alterations on lipid peroxidation and oxidative stress markers (malondialdehyde, superoxide dismutase, reduced glutathione, and catalase) was assessed by brain striatum homogenate."
• May Resveratrol modulates the sFRP4/Wnt signaling Pathway and preserves blood-brain barrier integrity in rats with ischemic stroke. (European journal of pharmacology, 2026, PMID 42114733): "Resveratrol significantly reduced the levels of inflammatory factors, lowered the malondialdehyde (MDA) level, and increased the levels of glutathione (GSH) and total antioxidant capacity (T-AOC)."
• May Mechanism of CRM1 Inhibition by Lansoprazole and Its Synergy with Cisplatin in Gastric Cancer. (Journal of medicinal chemistry, 2026, PMID 42134807): "Since the compound is susceptible to inhibition by glutathione (GSH), we designed a combination strategy where cisplatin, by depleting GSH, synergistically enhanced CRM1 inhibition."
• May Clemizole Mitigates Traumatic Brain Injury by Inhibiting Oxidative Stress, Neuroinflammation, and Apoptosis. (ACS chemical neuroscience, 2026, PMID 41968889): "Biochemical assays revealed that Clemizole dose-dependently reduced nitrite and MDA levels while restoring GSH, indicating attenuation of oxidative stress."
• May Synovial Targeting and Redox-Triggered Release: A Dual Strategy in Peptide-Drug Conjugates for Rheumatoid Arthritis. (Bioconjugate chemistry, 2026, PMID 42030082): "Both new conjugates exhibited markedly improved plasma stability and demonstrated selective, glutathione-triggered release of SIN, with LC-MS confirming an accelerated and more complete release from the dual-disulfide conjugate."